Dosing & Uses
Dosage Forms & Strengths
powder for injection
Candidemia, Candidal Peritonitis, Intra-Abdominal Abscess
Day 1: 200 mg IV infusion, THEN
Day 2 Onwards: 100 mg/day IV
Generally continue 14 days after last positive culture
Day 1: 100 mg IV infusion, THEN
Day 2 Onwards: 50 mg/day IV
Minimum 14 day treatment, at least 7 days following resolution of symptoms
Safety and efficacy not established; limited data suggest off-label dose of 3 mg/m²/dose IV loading dose, then 1.5 mg/m²/dose IV once daily
Serious - Use Alternative
Significant - Monitor Closely
- Diarrhea (3%)
- Hypokalemia (3%)
- Abnl LFTs (2%)
Esophageal Candidiasis treatment
- Headache (1%)
- Nausea (1%)
- Neutropenia (1%)
- Rash (1%)
Frequency Not Defined
Possible histamine-mediated symptoms reported including rash, urticaria, flushing, pruritus, bronchospasm, dyspnea, and hypotension; infrequent when infusion rate does not exceed 1.1 mg/minute.
Hypersensitivity to any component or other echinocandins
Abnormal LFTs observed; monitor for potential hepatic problems
May cause bronchospasm
Not studied for Candida-caused endocarditis, osteomyelitis or meningitis
Not for bolus administration
Pregnancy & Lactation
Pregnancy Category: C
Lactation: not known if distributed in breast milk, use caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Vd: 30-50 L
Half-Life, distribution: 30 min-1 hr
Half-Life, terminal elim: 40-50 hr
Protein Bound: 84%
Peak Plasma: 8.6 mg/L (on 200 mg/100 mg dosing regimen)
Clearance: 1 L/hr
Metabolism: not hepatically, not a CYP3A4 substrate
Excretion: feces 30%, very low in urine
Mechanism of Action
Echinocandin - inhibits synthesis of 1,3-beta-D-glucan, an essential component of fungal cell walls
Aseptically reconstitute each 50 mg vial with 15 mL supplied diluent to obtain a 3.33 mg/mL solution
May store at 25°C (77°F) - do not freeze
Administer within 24 hr post-reconstitution
Dilute further by transferring aseptically in a bag or bottle containing D5W or NS to provide an infusion solution of 0.5 mg/mL
Discard if particulate matter or discoloration appears
Infuse at NMT 1.1 mg/min
Do not give bolus
Unopened vials, reconstituted vials & diluted solution may be stored at 25°C (77°F) - do not freeze
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs